Menu
GeneBe

SLC6A4

solute carrier family 6 member 4, the group of Solute carrier family 6

Basic information

Region (hg38): 17:30194318-30236002

Previous symbols: [ "HTT", "OCD1" ]

Links

ENSG00000108576NCBI:6532OMIM:182138HGNC:11050Uniprot:P31645AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • autism spectrum disorder (Disputed Evidence), mode of inheritance: AD

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SLC6A4 gene.

  • Behavior disorder (113 variants)
  • Inborn genetic diseases (10 variants)
  • not provided (5 variants)
  • Obsessive-compulsive disorder (2 variants)
  • Obsessive-compulsive disorder, susceptibility to (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SLC6A4 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
9
clinvar
4
clinvar
13
missense
24
clinvar
2
clinvar
26
nonsense
0
start loss
0
frameshift
1
clinvar
1
inframe indel
0
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
3
1
4
non coding
59
clinvar
13
clinvar
6
clinvar
78
Total 0 1 93 19 6

Variants in SLC6A4

This is a list of pathogenic ClinVar variants found in the SLC6A4 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
17-30194565-T-C Behavior disorder Uncertain significance (Jan 13, 2018)889138
17-30194625-A-G Behavior disorder Uncertain significance (Jan 13, 2018)889813
17-30195008-C-G Behavior disorder Likely benign (Jan 12, 2018)889814
17-30195138-A-C Behavior disorder Uncertain significance (Jan 13, 2018)889815
17-30195229-C-T Behavior disorder Uncertain significance (Jan 12, 2018)889816
17-30195409-T-C Behavior disorder Likely benign (Jan 13, 2018)889817
17-30195486-C-T Behavior disorder Uncertain significance (Jan 13, 2018)889818
17-30195499-G-A Behavior disorder Benign (Jan 12, 2018)889819
17-30195620-G-A Behavior disorder Uncertain significance (Jan 13, 2018)889820
17-30195753-T-C Behavior disorder Likely benign (Jan 12, 2018)891367
17-30195961-C-T Behavior disorder Uncertain significance (Jan 13, 2018)891368
17-30196044-C-G Behavior disorder Uncertain significance (Jan 15, 2018)891369
17-30196067-T-C Behavior disorder Benign (Jan 12, 2018)891370
17-30196068-G-A Behavior disorder Benign (Jan 13, 2018)891371
17-30196103-T-C Behavior disorder Benign (Jan 12, 2018)891372
17-30196264-C-G Behavior disorder Uncertain significance (Mar 30, 2018)891373
17-30196296-C-A Behavior disorder Benign (Jan 13, 2018)891374
17-30196344-G-A Behavior disorder Uncertain significance (Jan 13, 2018)322503
17-30196362-C-T Behavior disorder Uncertain significance (Jan 13, 2018)891619
17-30196364-AT-A Behavior disorder Uncertain significance (Jun 14, 2016)322505
17-30196364-A-AT Behavior disorder Uncertain significance (Jun 14, 2016)322504
17-30196371-T-G Behavior disorder Uncertain significance (Jan 13, 2018)322506
17-30196437-G-A Behavior disorder Uncertain significance (Jan 12, 2018)322507
17-30196523-A-G Behavior disorder Uncertain significance (Jan 13, 2018)891620
17-30196556-A-G Behavior disorder Uncertain significance (Jan 13, 2018)891621

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SLC6A4protein_codingprotein_codingENST00000401766 1341684
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.2460.7541257310171257480.0000676
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense1.932723780.7200.00002244107
Missense in Polyphen94159.70.588591854
Synonymous0.5171471550.9470.00001021263
Loss of Function4.12833.80.2360.00000173359

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0001780.000177
Ashkenazi Jewish0.000.00
East Asian0.0001090.000109
Finnish0.000.00
European (Non-Finnish)0.00007050.0000703
Middle Eastern0.0001090.000109
South Asian0.00003270.0000327
Other0.0001630.000163

dbNSFP

Source: dbNSFP

Function
FUNCTION: Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner. {ECO:0000269|PubMed:17506858, ECO:0000269|PubMed:18227069, ECO:0000269|PubMed:19270731, ECO:0000269|PubMed:27049939}.;
Pathway
Citalopram Pathway, Pharmacokinetics;Serotonergic synapse - Homo sapiens (human);Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics;Fluoxetine Pathway, Pharmacokinetics;Venlafaxine Pathway, Pharmacokinetics;Levomethadyl Acetate Action Action Pathway;Fluoxetine Action Pathway;Citalopram Action Pathway;Escitalopram Action Pathway;Imipramine Action Pathway;Desipramine Action Pathway;Levallorphan Action Pathway;Dimethylthiambutene Action Pathway;Ethylmorphine Action Pathway;Pentazocine Action Pathway;Naltrexone Action Pathway;Buprenorphine Action Pathway;Alvimopan Action Pathway;Naloxone Action Pathway;Dihydromorphine Action Pathway;Imipramine Metabolism Pathway;Desipramine Metabolism Pathway;Citalopram Metabolism Pathway;Nicotine Action Pathway;Nalbuphine Action Pathway;Ketobemidone Action Pathway;Lidocaine (Local Anaesthetic) Action Pathway;Mepivacaine Action Pathway;Chloroprocaine Action Pathway;Cocaine Action Pathway;Dibucaine Action Pathway;Levobupivacaine Action Pathway;Benzocaine Action Pathway;Bupivacaine Action Pathway;Levorphanol Action Pathway;Propoxyphene Action Pathway;Tramadol Action Action Pathway;Diphenoxylate Action Pathway;Anileridine Action Pathway;Methadone Action Pathway;Oxycodone Action Pathway;Oxybuprocaine Action Pathway;Prilocaine Action Pathway;Procaine Action Pathway;Proparacaine Action Pathway;Ropivacaine Action Pathway;Codeine Action Pathway;Morphine Action Pathway;Heroin Action Pathway;Venlafaxine Metabolism Pathway;Fluoxetine Metabolism Pathway;Alfentanil Action Pathway;Oxymorphone Action Pathway;Hydrocodone Action Pathway;Hydromorphone Action Pathway;Sufentanil Action Pathway;Remifentanil Action Pathway;Fentanyl Action Pathway;Carfentanil Action Pathway;3-Methylthiofentanyl Action Pathway;Methadyl Acetate Action Pathway;Dezocine Action Pathway;Serotonin Transporter Activity;Synaptic Vesicle Pathway;Nuclear Receptors Meta-Pathway;NRF2 pathway;Selective serotonin reuptake inhibitors lead to several adverse outcomes;Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways;Monoamine Transport;Neuronal System;Tryptophan metabolism;Serotonin clearance from the synaptic cleft;Neurotransmitter clearance;Transmission across Chemical Synapses (Consensus)

Recessive Scores

pRec
0.559

Intolerance Scores

loftool
0.528
rvis_EVS
-0.6
rvis_percentile_EVS
18.06

Haploinsufficiency Scores

pHI
0.127
hipred
Y
hipred_score
0.762
ghis
0.445

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
gene_indispensability_pred
E
gene_indispensability_score
0.803

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Slc6a4
Phenotype
endocrine/exocrine gland phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); muscle phenotype; homeostasis/metabolism phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); normal phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);

Gene ontology

Biological process
response to hypoxia;serotonin transport;response to nutrient;memory;circadian rhythm;response to toxic substance;positive regulation of gene expression;positive regulation of serotonin secretion;monoamine transport;negative regulation of cerebellar granule cell precursor proliferation;negative regulation of synaptic transmission, dopaminergic;response to estradiol;social behavior;neurotransmitter biosynthetic process;vasoconstriction;response to drug;sperm ejaculation;negative regulation of neuron differentiation;positive regulation of cell cycle;negative regulation of organ growth;brain morphogenesis;protein complex oligomerization;protein homooligomerization;serotonin uptake;transmembrane transport;cellular response to retinoic acid;cellular response to cGMP;regulation of thalamus size
Cellular component
cytosol;plasma membrane;integral component of plasma membrane;endosome membrane;endomembrane system;neuron projection;membrane raft;integral component of postsynaptic membrane;integral component of presynaptic membrane;serotonergic synapse
Molecular function
serotonin:sodium symporter activity;protein binding;monoamine transmembrane transporter activity;myosin binding;syntaxin-1 binding;Rab GTPase binding;cocaine binding;protein homodimerization activity;metal ion binding;nitric-oxide synthase binding;actin filament binding;serotonin binding